Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Fungal Infection Reports
Published in: Current Fungal Infection Reports 3/2013

01-09-2013 | Invited Commentary

Report From the 39th Annual Meeting of the European Group for Blood and Marrow Transplantation, London, 7–10 April 2013

Author: Sue Lyon

Published in: Current Fungal Infection Reports | Issue 3/2013

Login to get access

Abstract

Antifungal prophylaxis reduces the risks of invasive fungal infection (IFI), all-cause mortality and fungal-related mortality in highly immunosuppressed haemato-oncology patients, but questions remain about the role of therapeutic drug monitoring in this patient population. There is also continuing debate concerning the benefits and risks of empirical versus pre-emptive antifungal therapy when breakthrough IFI occurs during prophylaxis. These topics were discussed during the 39th Annual Meeting of the European Group for Blood and Marrow Transplantation, held in London in April 2013.
Literature
1.
Robenshtok E, Gafter-Gvili A, Goldberg E, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol. 2007;25:5471–89.PubMedCrossRef
2.
De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–21.PubMedCrossRef
3.
4.
Sanchez-Ortega I, Cuesta I, Patino B, et al. Clinical efficacy and management of primary antifungal prophylaxis with posaconazole in high-risk haematology patients. 39th Annual Meeting of the European Group for Blood and Marrow Transplantation, London 2013.
5.
Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348–59.PubMedCrossRef
6.
Ullman AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prohylaxis in severe graft versus host disease. N Engl J Med. 2007;356:355–47.
7.
Marks DI, Pagliuca A, Kibbler CC, et al. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol. 2011;155:318–27.PubMedCrossRef
8.
Wingard JR, Carter SL, Walsh TJ, et al. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood. 2010;116:5111–8.PubMedCrossRef
9.
Trifilio S, Pennick G, Pi J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer. 2007;109:1532–5.PubMedCrossRef
10.
Mitsani D, Nguyen MH, Shields RK, et al. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity. Antimicrob Agents Chemother. 2012;56:2371–7.PubMedCrossRef
11.
Walsh TJ, Raad I, Patterson TF, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controled trial. Clin Infect Dis. 2007;44:2–12.PubMedCrossRef
12.
Cornely OA, Ullmann AJ. Lack of evidence for exposure-response relationship in the use of posaconazole as prophylaxis against invasive fungal infections. Clin Pharmacol Ther. 2011;89:351–2.PubMedCrossRef
13.
Cornely OA, Helfgott D, Langston A, et al. Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection. Antimicrob Agents Chemother. 2012;56:2652–8.PubMedCrossRef
14.
Campoli P, Al Abdallah Q, Robitaille R, et al. Concentration of antifungal agents within host cell membranes: a new paradigm governing the efficacy of prophylaxis. Antimicrob Agents Chemother. 2011;55:5732–9.PubMedCrossRef
15.
Campoli P, Attias O, Kristof AS, Perlin D, Sheppard DC. Posaconazole concentrates within the endoplasmic reticulum of host and fungal cells. 22nd European Congress of Clinical Microbiology and Infectious Diseases. London 2013.
16.
Rieger CT, Huppmann S, Peterson L, Rieger H, Ostermann H. Classification of invasive fungal disease in patients with acute myeloid leukaemia. Mycoses. 2011;54:e92–8.PubMedCrossRef
17.
Rieger CT, Ostermann H. Empiric vs. preemptive antifungal treatment: an appraisal of treatment strategies in haematological patients. Mycoses. 2008;51 suppl 1:31–4.PubMedCrossRef
18.
Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50:1091–100.PubMedCrossRef
19.
Pizzo PA, Robichaud KJ, Gill F, Witebsky F. Empiric antibiotic and antifungal therapy for cancer patients with prlonged fever and granulocytopenia. Am J Med. 1982;72:1010–111.CrossRef
20.
EORTC International Antimicrobial Therapy Cooperative Group. Empriric antifungal therapy in febrile graulocytopenic patients. Am J Med. 1989;86(Pt1):668–72.
21.
Walsh TJ, Finberg RW, Arndt C, et al. Lipsomal amphotericin B for empircal tgherapy in patients with persistent fever and neutropenia. N Engl J Med. 1999;340:1837–8.CrossRef
22.
Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002;351:1391–402.CrossRef
23.
Walsh TJ, Teppler H, Donowitz GR, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004;351.
24.
Cordonnier C, Pautas C, Maury S, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis. 2009;48:1042–51.PubMedCrossRef
25.
Teo C, Wong ZX, Poon MLM, Tan B. Comparative analysis of fluconazole versus posaconazole as antifungal prophylaxis in allogeneic haematopeoietic cell transplant patients. 39th Annual Meeting of the European Group for Blood and Marrow Transplantation, London 2013.
26.
Glass B, Bastubbe V, Dingeldein S, Nickelsen M, Zeis M, Schmitz N. Results of antimycotic prophylaxis with posaconazole in patients with severe graft-versus-host disease (GVHD): a single centre analysis. 39th Annual Meeting of the European Group for Blood and Marrow Transplantation, London 2013.
Metadata
Title
Report From the 39th Annual Meeting of the European Group for Blood and Marrow Transplantation, London, 7–10 April 2013
Author
Sue Lyon
Publication date
01-09-2013
Publisher
Springer US
Published in
Current Fungal Infection Reports / Issue 3/2013
Print ISSN: 1936-3761
Electronic ISSN: 1936-377X
DOI
https://doi.org/10.1007/s12281-013-0147-9

Other articles of this Issue 3/2013

Current Fungal Infection Reports 3/2013 Go to the issue

Clinical Lab Issues (M Brandt, Section Editor)

Candida africana: Is It a Fungal Pathogen?

Advances in Diagnosis of Invasive Fungal Infections (U Binder, Section Editor)

Galactomannan-Based and PCR-Based Assays in Bronchoalveolar Lavage to Diagnose Invasive Aspergillosis: Current Status and Future Prospects

Clinical Lab Issues (M Brandt, Section Editor)

Filamentous Basidiomycetes in the Clinical Laboratory

Clinical Lab Issues (M Brandt, Section Editor)

Current Thoughts in Fungal Keratitis: Diagnosis and Treatment

Advances in Diagnosis of Invasive Fungal Infections (U Binder, Section Editor)

Update on Antifungal Resistance and its Clinical Impact

Clinical Lab Issues (M Brandt, Section Editor)

Coelomycete Fungi in the Clinical Lab
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits